drugset / Trial / NCT01189240
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase I/II trial is studying the side effects and the best dose of RO4929097 to see how well it works when given together with bevacizumab compared to bevacizumab alone in treating patients with progressive or recurrent malignant glioma. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving RO4929097 together with bevacizumab may kill more tumor cells.
Timeline
- Start
- 2010-12
- Primary completion
- 2013-01
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | RG4733 | Small molecule | 5 mg | Oral |
| Subject | RG4733 | Small molecule | 10 mg | Oral |
| Subject | RG4733 | Small molecule | 20 mg | Oral |